Vaccine project targeting congenital infection scrapped in late-stage trial – “Clearly disappointed”

Hope for the first vaccine against the world’s most common congenital infection has taken a serious hit

Agreement in the EU on eight years of data exclusivity for new medicines

New pharmaceuticals will be covered by eight years of data exclusivity, according to the proposed new pharmaceutical legislation that EU countries have now agre...

New Horizons in Biologics & Bioprocessing incl. Advanced Therapies: Stockholm (2025)

US Health Secretary Kennedy dismisses all vaccine experts – assembles new committee

Robert F. Kennedy Jr. has dismissed all 17 members of the CDC’s vaccine advisory panel. A new group of experts will be appointed directly by the Health Secretar...

The First Multi-Technology System from ZEISS

Microscope and measuring machine in one.

FDA approves Gilead’s HIV injection: “Historic day”

Gilead Sciences’ preventive HIV drug, lenacapavir, was approved on Wednesday by the U.S. Food and Drug Administration (FDA), sparking new hope for finally break...

Advanced workflow automation and scalable image analysis in spatial biology

ZEISS and Concept Life Sciences announce partnership.

An organ seldom in the spotlight – but utterly vital

The kidneys consist of more than 40 types of cells and have more functions in the body than most people know. Julie Williams leads AstraZeneca’s work in preclin...

The scientist behind Novo Nordisk's obesity success: “I never stopped believing in GLP-1”

It took several years of failures in GLP-1 before Lotte Bjerre Knudsen and her colleagues found the right path – but when they did, it was a true breakthrough. ...

Positive EMA Decision for BioArctic's New Drug Candidate

Bioarctic's drug candidate for multiple system atrophy, exidavnemab, is recommended to be classified as an orphan drug, according to the European Medicines Agency (EMA).

ZEISS Lightfield 4D for instant volumetric high-speed imaging

Capturing physiological and neuronal processes in 3D.

100 years of Festo

The spirit of invention is deeply rooted in our corporate culture. Since our foundation, we have been setting benchmarks by developing innovative solutions that...

Explore our tailored program for Control 2025

Choose an innovation tour, or join our industry-specific guided tours.

Thermo Fisher-team flyttar in hos Astra Zeneca Bioventurehub – inleder samarbete

Amerikanska Thermo Fisher och Astra Zeneca Bioventurehub krokar arm i ett nytt FoU-partnerskap. Bolagen ska samlokalisera i Goco Health Innovation City, Göteborg.

Astra Zeneca avslutar tillverkning i Indien – lämnar in licensen

Astra Zeneca skyndar på planerna att avsluta sin produktion i Indien. Företaget avsäger sig nu sin tillverkningslicens i landet två år innan den skulle ha löpt ut.

ZEISS continues to drive digital era forward in ophthalmology

2 million digitally planned cataract cases in the U.S. alone.

Södertäljebolag tar in 440 miljoner inför klinisk cancerstudie

Cellterapibolaget Anocca har lyckats ta in närmare 440 miljoner kronor i en ny finansieringsrunda för att stödja kommande kliniska prövningar inom bukspottkörtelcancer.

Getinge and Neobiomics received Swecare's export awards

Two companies received awards during Swecare's annual conference.

Xspray tar in 130 miljoner inför USA-lansering

Forskningsbolaget Xspray Pharma genomför en företrädesemission på upp till 130 miljoner kronor. Huvudsyftet är att stödja en planerad lansering av cancerläkemed...

Several departures at the top at Nykode

Members of both the management and the board are leaving the Norwegian biotech company Nykode.

One last chance to register for the premier metrology event in 2024

ZEISS QUALITY INNOVATION SUMMIT.

ZEISS Connected Quality: One metrology hub

The new product family ZEISS CONNECTED QUALITY is the solution for quick and secure data exchange, quality management and efficient system monitoring.

Genterapi gav hörsel till barn med medfödd dövhet – elva av tolv förbättrades

Elva av tolv barn med medfödd dövhet uppvisade förbättringar i en studie där Regenerons genterapi mot ärftlig hörselnedsättning prövades. Nu planerar det amerik...

Efter förseningen – nu har Ascelia lämnat in sin FDA-ansökan

Efter flera turer och en studie som fick göras om har nu Ascelia Pharma till slut lämnat in en ansökan om marknadsgodkännande i USA för kontrastmedlet Orviglance.